Prevalence of Alzheimer’s disease pathology in the community

In a large Norwegian population study (11,486 plasma samples), plasma pTau217 was used to estimate Alzheimer’s disease neuropathological change (ADNC) prevalence: under 8% for ages 58–69.9, rising to 65.2% for those over 90, and 33.4% across the 70+ cohort. Within the 70+ group, 10.0% were classified as preclinical AD, 10.4% prodromal AD and 9.8% AD dementia; 909 of 8,949 (10.2%) met current eligibility criteria for disease‑modifying therapies (weighted estimate 11.1%). Findings highlight a sizeable addressable population for anti‑amyloid treatments, APOE ε4 and low eGFR associations with pTau217, and use of validated pTau217 cutoffs (0.40 and ≥0.63 pg/ml) — data that could inform demand forecasts, payer exposure and clinical adoption risk assessments for Alzheimer’s therapeutics.

Analysis

Market structure: Winners are diagnostic and lab-platform vendors that scale blood pTau217 (QTRX, large clinical labs like LH) and tau-targeted biotech (ALEC, PRTA) that benefit from faster, cheaper case-finding; established PET-only gatekeepers and niche imaging vendors lose discretionary volume. Estimated addressable pool ~11% of 70+ (HUNT) implies demand shock for diagnostics and DMT monitoring—if extrapolated to US/EU seniors, incremental annual treated patients could be millions, pressuring infusion capacity and MRI/MCA monitoring budgets within 12–36 months.

Risk assessment: Tail risks include major payer pushback (Medicare/CMS price/coverage limits) and assay-class action if PPV/NPV vary in diverse populations; both are low-probability but can cut peak revenue by 50%+. Short-term (0–3 months) volatility from guideline updates, medium (3–12 months) adoption/coverage decisions, long-term (1–5 years) structural demand for DMTs and diagnostics. Hidden dependency: renal dysfunction (eGFR <51) biases pTau217—market estimates that ignore CKD prevalence will misprice diagnostics adoption and payer risk.

trade implications: Direct play: overweight QTRX (diagnostics platform) and select tau-biotech ALEC on 12–24 month horizon; underweight or hedge large AD therapeutics exposed names (BIIB) because pricing and uptake remain uncertain. Use pair trade long QTRX / short BIIB to capture diagnostic upside vs therapeutic pricing/regulatory risk. Options: 3–9 month call spreads on QTRX to limit capital and 3-month put spreads on BIIB as asymmetric downside protection.

contrarian: Consensus overestimates immediate treated population—real-world uptake likely 20–40% of eligibility in first 2 years due to access, adverse events (ARIA) and payer constraints; diagnostics upside is underpriced today. Historical parallel: PET adoption took >5 years—blood-based tests may compress to 1–3 years but only with favorable reimbursement; unintended consequence: rapid case-finding could trigger tougher price negotiations that cap long-term drug upside.

Key Decisions for Investors

• Establish a 1–2% long position in Quanterix (QTRX) within 30 days, target +40% upside over 12 months; implement a 25% stop-loss and consider financing via a 6–9 month call spread if implied vol is high.
• Initiate a 1% long position in Alector (ALEC) on any >10% pullback, horizon 12–24 months to play tau therapeutics; trim to breakeven on positive Phase readouts or if payer guidance is unfavorable.
• Construct a pair trade: long QTRX (1%) and short BIIB (1%) to capture diagnostic adoption vs therapeutic pricing/regulatory risk; hedge the BIIB leg with a 3-month put spread (10–15% OTM) to cap cost.
• Purchase a 3–6 month protection on biotech exposure: buy BIIB 3-month put spread (limit cost to <1% portfolio) ahead of upcoming US/EU coverage decisions; monitor CMS/payer statements over next 90 days and EU price negotiations over 6–12 months.